Challenges to the development of new agents for molecularly defined patient subsets: Lessons from BRCA1/2-associated breast cancer.
Journal of Clinical Oncology.
Times cited: 16
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial.
Times cited: 1071